Literature DB >> 11261526

Olanzapine-lnduced hyperglycemic nonketonic coma.

J Roefaro1, S M Mukherjee.   

Abstract

OBJECTIVE: To report a case of olanzapine-induced hyperglycemia leading to a hyperosmolar, hyperglycemic, nonketonic coma. CASE
SUMMARY: A 51-year-old, 85.5-kg (ideal body weight 79.9 kg), white man presented to a Veterans Affairs hospital with a serum glucose concentration of 1596 mg/dL. Soon thereafter, he went into a hyperosmolar, hyperglycemic, nonketonic coma. Olanzapine therapy had been instituted less than six months prior to this event; approximately two months before this event, his blood glucose was 108 mg/dL. Eight days after stopping olanzapine, the glucose concentration returned to normal, and the patient no longer required insulin nor any other glucose-lowering agents. DISCUSSION: The insulin resistance caused by olanzapine is normally attributed to the weight gain associated with the drug. In this patient, it appears that olanzapine caused hyperglycemia by a mechanism other than weight gain.
CONCLUSIONS: This case report and others from the literature suggest that olanzapine therapy may induce hyperglycemia in some patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11261526     DOI: 10.1345/aph.10178

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  Hyperosmolar hyperglycemic state in a patient taking risperidone.

Authors:  Joseph M Cerimele
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 2.  Acute hyperglycemia associated with short-term use of atypical antipsychotic medications.

Authors:  T Vivian Liao; Stephanie V Phan
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 3.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment.

Authors:  Francisco J Pasquel; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2014-11       Impact factor: 19.112

Review 5.  Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

Authors:  Kristina Melkersson; Marja-Liisa Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Hyperglycemia associated with olanzapine treatment.

Authors:  P N Suresh Kumar; Biju Thomas
Journal:  Indian J Psychiatry       Date:  2011-04       Impact factor: 1.759

7.  Silencing of sterol glycosyltransferases modulates the withanolide biosynthesis and leads to compromised basal immunity of Withania somnifera.

Authors:  Gaurav Singh; Manish Tiwari; Surendra Pratap Singh; Surendra Singh; Prabodh Kumar Trivedi; Pratibha Misra
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

8.  A case report and literature review of olanzapine-associated hyperglycemia with previous history of gestational diabetes.

Authors:  Jennifer N Alastanos; Devika Suri; Hayato DeLellis; Andrea Mapugay
Journal:  Ment Health Clin       Date:  2022-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.